Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131932 | 1.00 | FFAR1 (0.57) | FFAR1HCAR2HTR2CHTR2BGPR88 | |
| SCHEMBL4134503 | 0.85 | HCAR2 (0.52) | HCAR2HTR2CHTR2BGPR88SLC6A4 | |
| SCHEMBL4134501 | 0.85 | HCAR2 (0.52) | HCAR2HTR2CHTR2BGPR88SLC6A4 | |
| SCHEMBL15091458 | 0.85 | FFAR1 (0.52) | FFAR1HCAR2GPR88 | |
| SCHEMBL15091460 | 0.85 | FFAR1 (0.52) | FFAR1HCAR2GPR88 | |
| SCHEMBL25882438 | 0.81 | HCAR2 (0.45) | HCAR2SLC6A4SLC6A3 | |
| SCHEMBL1820513 | 0.81 | SLC6A4 (0.51) | HCAR2HTR2CHTR2BSLC6A4SLC6A2 | |
| SCHEMBL1820515 | 0.81 | SLC6A4 (0.51) | HCAR2HTR2CHTR2BSLC6A4SLC6A2 | |
| SCHEMBL1820510 | 0.81 | SLC6A4 (0.51) | HCAR2HTR2CHTR2BSLC6A4SLC6A2 | |
| SCHEMBL2034678 | 0.79 | FFAR1 (0.70) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | FFAR1 4727/4885HCAR2 882/4885HTR2C 4222/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | FFAR1 1439/4885HCAR2 413/4885HTR2C 1304/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | FFAR1 43/4885HCAR2 22/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.